FBXW7 and colorectal adenocarcinoma: Moreover, ∼20% of patients with colorectal adenocarcinoma have somatic FBXW7 mutations (Tate et al., 2019), with altered FBXW7 expression contributing to tumor development and progression, while loss-of-function mutations are predicted to be deleterious.